Updates on HER2-Directed ADCs Across Solid Tumors - Episode 5
ADCs Targeting GI Cancers
Dr Parikh discusses the history of ADCs for treating GI cancers with a focus on the data for T-DXd and its role in treating these cancers.
Video content above is prompted by the following:
- Please review the data for T-DM1 for:
- HER2+ advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocaricoma: GATSBY; Shah-Gastric Cancer_2019: Biomarker analysis of GATSBY
- T-DM1 + Pertuzumab for HER2-amplified colorectal cancer: HERACLES-B trial
- Please review the data for T-DXd for:
- HER2+ gastric or GEJ: DESTINY-Gastric01; Shitara_Nature Med_2024: Biomarker Analysis of DESTINY-Gastric01 and DESTINY-Gastric02
- Unresectable or metastatic HER2+ CRC: DESTINY-CRC01 1. DESTINY-CRC02 – Raghav_ASCO 2023
- HER2+ and HER2-low GC: DESTINY-Gastric03 Janjigian ASCO 2024
- Retrospective Cohort Study EN-DEAVOR: Nakanishi ASCO 2024
- What is the potential for HER2-targeting ADCs in other GI cancers?
- Biliary Tract Cancers, Pancreatic
- PanTumor02: Meric-Bernstam_J Clin Oncol_2024; a. BTC and PC Cohort Outcomes: Oh ASCO 2024 #4090
- HERB trial (BTC): Ohba_ASCO2022
- Biliary Tract Cancers, Pancreatic
- Where do HER2-directed ADCs fit into the treatment armamentarium for GI cancers?
- Is there an unmet need ADCs could help fill?
Related Content:
